Intratrabecular bone remodeling - a previously overlooked mode of remodeling hyperactivated by parathyroid hormone.

Thomsen LK, Laursen KS, Sikjær T, Thomsen JS, Andreasen CM, Loundagin L, Harrison K, Underbjerg L, Boel LWT, Hansen D, Dempster D, Cosman F and 6 more

Show all authors

Wei X, Rizvi AR, Kersh M, Cooper DML, Rejnmark L, Andersen TL

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research12 May 2026

PMID42119027DOI10.1093/jbmr/zjag081PepBankPUB-42119027

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism patients, median eroded pores were 7.7% after rhPTH(1-84) versus 0.0% after conventional treatment at 6 months.
In plain wordsIn hypoparathyroidism patients, eroded pores were more frequent with rhPTH(1-84) than conventional treatment at 6 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseEroded pores
Study
n: not reported in source
Comparator
Conventional treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 μg daily · injection · 6 monthsAs given in this study (human).
Measurements
Eroded pores
7.7%
rhPTH
Eroded pores
0%
conventional treatment
Source sentences
Summary
After 6-months of PTH- versus conventional treatment, a median 7.7% versus 0.0% were eroded pores, 69.1% versus 0.0% were eroded-formative pores, 12.9% versus 0.0% were formative pores and 0.9% versus 81.2% were quiescent pores.
2 context sentences(design, population, supporting numbers)
Summary · context
This study primarily utilizes iliac crest bone biopsies collected from a clinical trial where patients with hypoparathyroidism were randomized to receive daily injections with either 100μg rhPTH(1-84) or placebo as add-on to conventional therapy for 6 months.
Summary · context
In addition, further bone biopsies were collected from a 24-month open-label extension study, including patients receiving either only conventional treatment, continued rhPTH-treatment or discontinued rhPTH-treatment.
Report a problemFND-4211902703
02HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism patients, median eroded-formative pores were 69.1% after rhPTH(1-84) versus 0.0% after conventional treatment at 6 months.
In plain wordsIn hypoparathyroidism patients, eroded-formative pores were more frequent with rhPTH(1-84) than conventional treatment at 6 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseEroded-formative pores
Study
n: not reported in source
Comparator
Conventional treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 μg daily · injection · 6 monthsAs given in this study (human).
Measurements
Eroded-formative pores
69.1%
rhPTH
Eroded-formative pores
0%
conventional treatment
Source sentences
Summary
After 6-months of PTH- versus conventional treatment, a median 7.7% versus 0.0% were eroded pores, 69.1% versus 0.0% were eroded-formative pores, 12.9% versus 0.0% were formative pores and 0.9% versus 81.2% were quiescent pores.
2 context sentences(design, population, supporting numbers)
Summary · context
This study primarily utilizes iliac crest bone biopsies collected from a clinical trial where patients with hypoparathyroidism were randomized to receive daily injections with either 100μg rhPTH(1-84) or placebo as add-on to conventional therapy for 6 months.
Summary · context
In addition, further bone biopsies were collected from a 24-month open-label extension study, including patients receiving either only conventional treatment, continued rhPTH-treatment or discontinued rhPTH-treatment.
Report a problemFND-4211902704
03HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism patients, median formative pores were 12.9% after rhPTH(1-84) versus 0.0% after conventional treatment at 6 months.
In plain wordsIn hypoparathyroidism patients, formative pores were more frequent with rhPTH(1-84) than conventional treatment at 6 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseFormative pores
Study
n: not reported in source
Comparator
Conventional treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 μg daily · injection · 6 monthsAs given in this study (human).
Measurements
Formative pores
12.9%
rhPTH
Formative pores
0%
conventional treatment
Source sentences
Summary
After 6-months of PTH- versus conventional treatment, a median 7.7% versus 0.0% were eroded pores, 69.1% versus 0.0% were eroded-formative pores, 12.9% versus 0.0% were formative pores and 0.9% versus 81.2% were quiescent pores.
2 context sentences(design, population, supporting numbers)
Summary · context
This study primarily utilizes iliac crest bone biopsies collected from a clinical trial where patients with hypoparathyroidism were randomized to receive daily injections with either 100μg rhPTH(1-84) or placebo as add-on to conventional therapy for 6 months.
Summary · context
In addition, further bone biopsies were collected from a 24-month open-label extension study, including patients receiving either only conventional treatment, continued rhPTH-treatment or discontinued rhPTH-treatment.
Report a problemFND-4211902705
04HumanRandomized controlled trialEfficacy outcome
In hypoparathyroidism patients, median quiescent pores were 0.9% after rhPTH(1-84) versus 81.2% after conventional treatment at 6 months.
In plain wordsIn hypoparathyroidism patients, quiescent pores were less frequent with rhPTH(1-84) than conventional treatment at 6 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseQuiescent pores
Study
n: not reported in source
Comparator
Conventional treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 μg daily · injection · 6 monthsAs given in this study (human).
Measurements
Quiescent pores
0.9%
rhPTH
Quiescent pores
81.2%
conventional treatment
Source sentences
Summary
After 6-months of PTH- versus conventional treatment, a median 7.7% versus 0.0% were eroded pores, 69.1% versus 0.0% were eroded-formative pores, 12.9% versus 0.0% were formative pores and 0.9% versus 81.2% were quiescent pores.
2 context sentences(design, population, supporting numbers)
Summary · context
This study primarily utilizes iliac crest bone biopsies collected from a clinical trial where patients with hypoparathyroidism were randomized to receive daily injections with either 100μg rhPTH(1-84) or placebo as add-on to conventional therapy for 6 months.
Summary · context
In addition, further bone biopsies were collected from a 24-month open-label extension study, including patients receiving either only conventional treatment, continued rhPTH-treatment or discontinued rhPTH-treatment.
Report a problemFND-4211902706
05HumanNon-randomized trialEfficacy outcome
In patients with hypoparathyroidism receiving rhPTH(1-84), intratrabecular porosity increased 18-fold after 6 months.
In plain wordsIn patients with hypoparathyroidism receiving rhPTH(1-84), porosity within bone trabeculae increased 18-fold after 6 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseIntratrabecular porosity at 6 months
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 μg daily · injection · 6 monthsAs given in this study (human).
Measurements
Porosity increase
18 fold
6 months
Source sentences
Summary
Histomorphometry demonstrated that PTH-treatment induced an 18-fold and 36-fold increase in intratrabecular porosity after 6 and 30 months of treatment, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study primarily utilizes iliac crest bone biopsies collected from a clinical trial where patients with hypoparathyroidism were randomized to receive daily injections with either 100μg rhPTH(1-84) or placebo as add-on to conventional therapy for 6 months.
Summary · context
In addition, further bone biopsies were collected from a 24-month open-label extension study, including patients receiving either only conventional treatment, continued rhPTH-treatment or discontinued rhPTH-treatment.
Report a problemFND-4211902701
06HumanNon-randomized trialEfficacy outcome
In patients with hypoparathyroidism receiving rhPTH(1-84), intratrabecular porosity increased 36-fold after 30 months.
In plain wordsIn patients with hypoparathyroidism receiving rhPTH(1-84), porosity within bone trabeculae increased 36-fold after 30 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseIntratrabecular porosity at 30 months
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injection · 30 monthsAs given in this study (human).
Measurements
Porosity increase
36 fold
30 months
Source sentences
Summary
Histomorphometry demonstrated that PTH-treatment induced an 18-fold and 36-fold increase in intratrabecular porosity after 6 and 30 months of treatment, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study primarily utilizes iliac crest bone biopsies collected from a clinical trial where patients with hypoparathyroidism were randomized to receive daily injections with either 100μg rhPTH(1-84) or placebo as add-on to conventional therapy for 6 months.
Summary · context
In addition, further bone biopsies were collected from a 24-month open-label extension study, including patients receiving either only conventional treatment, continued rhPTH-treatment or discontinued rhPTH-treatment.
Report a problemFND-4211902702
07HumanNon-randomized trialEfficacy outcome
In hypoparathyroidism patients, withdrawal of rhPTH(1-84) normalized intratrabecular remodeling to levels similar to conventional therapy.
In plain wordsIn hypoparathyroidism patients, withdrawal of rhPTH(1-84) returned intratrabecular remodeling to levels similar to conventional therapy.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Direction not reportedRemodeling after withdrawal
Study
n: not reported in source
Comparator
Conventional therapy
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
PTH-treatment withdrawal normalized the intratrabecular remodeling to levels similar to conventional therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
This study primarily utilizes iliac crest bone biopsies collected from a clinical trial where patients with hypoparathyroidism were randomized to receive daily injections with either 100μg rhPTH(1-84) or placebo as add-on to conventional therapy for 6 months.
Summary · context
In addition, further bone biopsies were collected from a 24-month open-label extension study, including patients receiving either only conventional treatment, continued rhPTH-treatment or discontinued rhPTH-treatment.
Report a problemFND-4211902707
08HumanObservational studyMechanism
In hypoparathyroidism patients, intratrabecular remodeling parameters correlated positively with rhPTH(1-84)-induced trabecular mineralization.
In plain wordsIn hypoparathyroidism patients, remodeling parameters were positively linked to rhPTH(1-84)-induced trabecular mineralization.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseRemodeling association with mineralization
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
Intratrabecular remodeling parameters showed a positive correlation with PTH-induced trabecular mineralization and a negative correlation with active vitamin D-supplementary doses.
2 context sentences(design, population, supporting numbers)
Summary · context
This study primarily utilizes iliac crest bone biopsies collected from a clinical trial where patients with hypoparathyroidism were randomized to receive daily injections with either 100μg rhPTH(1-84) or placebo as add-on to conventional therapy for 6 months.
Summary · context
In addition, further bone biopsies were collected from a 24-month open-label extension study, including patients receiving either only conventional treatment, continued rhPTH-treatment or discontinued rhPTH-treatment.
Report a problemFND-4211902709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

PepBank is a research reference. Talk to a doctor before you use any peptide.